Skip to content
PubMed This is a summary of 22 peer-reviewed journal articles Updated
Ophthalmology

Can LHON Mothers Pass It On—and Will Children Have Symptoms?

At a Glance

Women who carry a LHON mitochondrial variant can pass it to their children, but inheritance does not guarantee vision loss. Risk varies by sex, the specific variant, family history, age, and exposures such as smoking, so genetic counseling and prompt evaluation of new vision changes are important.

Yes, if you are a woman carrying a Leber hereditary optic neuropathy (LHON) pathogenic variant (often called a “mutation”), you can pass it to your children. However, passing on the genetic variant does not mean your children will inevitably lose their vision. Because of a phenomenon called incomplete penetrance, a child can inherit the variant and never experience symptoms.

What This Means for Each Child

Every child inherits their mitochondria (the energy-producing centers of cells) exclusively from their mother [1]. How this affects your children depends on two key concepts:

  • The amount of the variant inherited: If all of your mitochondrial DNA carries the LHON variant (a state called homoplasmy), you will generally pass the variant to all of your children. If you have a mixture of normal and variant mitochondrial DNA (called heteroplasmy), the amount of the variant passed to each child can vary, and some children may not inherit a detectable level of the variant at all [2][3].
  • Inheriting the variant does not guarantee symptoms: Even if a child inherits a high level of the variant, they may remain perfectly healthy and asymptomatic throughout their life [4].

Who is Most Likely to Develop Symptoms?

The chance of developing vision loss from LHON is strongly influenced by sex. Males are significantly more likely to develop symptoms than females [4].

Broad lifetime estimates suggest that roughly 50% of male carriers and about 10% of female carriers will eventually experience vision loss [5]. However, these are approximate population-level figures. They cannot predict whether or when one particular child will develop symptoms. An individual’s true risk depends on the exact LHON variant, their broader genetic background, their age, and their family history [5][6].

The exact reason for this sex difference is still under investigation. One proposed explanation is that the female hormone estrogen might help boost mitochondrial function, potentially partially compensating for the genetic defect [7]. Please note that this is a research hypothesis, and hormone therapy is not an established or recommended treatment to prevent LHON symptoms [8].

Factors Associated with Risk: What You Can Do

While you cannot control the genes your children inherit, there are environmental exposures associated with a higher risk of an LHON carrier developing symptoms. Because LHON stresses the mitochondria, doctors recommend avoiding toxins that further impair mitochondrial function. However, it is important to understand that while avoiding these triggers is a prudent way to reduce risk, it cannot absolutely guarantee that symptoms will not develop, and no one should ever feel they caused their own or their child’s vision loss.

  • Smoking: Tobacco smoke is one of the most widely recognized modifiable risk factors [9][10]. Research indicates that smoking further reduces the energy output of cells carrying LHON variants. It is strongly recommended that carriers avoid smoking and secondhand smoke [10].
  • Alcohol: Heavy alcohol consumption has also been associated with an increased risk of developing symptoms in some studies [11][12]. While the evidence is less definitive than for smoking, many specialists advise limiting alcohol intake, though there is no clearly established “safe” threshold [12][6].
  • Medications: Certain medications and eye-drop preservatives (like benzalkonium chloride) can theoretically stress the mitochondria [13][14]. However, you should never stop or change prescribed medications without consulting your doctor [15]. Always inform your prescribing clinicians that your child is an LHON carrier so they can weigh the proven benefits of a medication against any potential mitochondrial risks [15].

If a Child Notices Vision Changes

Because the onset of LHON can be unpredictable, it is important to know what symptoms to watch for.

  • Early signs: LHON typically causes new, painless blurring or loss of central vision, a noticeable blind spot in the center of the visual field, or difficulty reading and recognizing colors (especially red and green) [16][17]. In children, the onset may sometimes be slower or more subtle [18].
  • What to do: Symptoms commonly start in one eye, and the second eye is usually affected within weeks to a few months [16]. If your child experiences any new, unexplained visual symptoms, do not wait for a routine exam—seek prompt evaluation from an ophthalmologist or a neuro-ophthalmologist [19][20]. Early evaluation can help establish a baseline, connect you with low-vision support, and allow for discussions about potential treatments or clinical trials.

Deciding on Genetic Testing

Deciding whether to test asymptomatic children for the LHON variant is a complex and highly personal choice. A positive test can confirm that the variant is present, but it cannot predict if or when symptoms will occur [21].

Because there is no guaranteed preventative treatment, testing asymptomatic minors raises important questions about privacy, potential psychological distress, and future implications [21][22]. These decisions should be made with a genetic counselor or a clinician familiar with mitochondrial diseases. A counselor can provide emotional support, help you navigate family discussions, and, if you are planning future pregnancies, discuss preconception options based on your personal values and geographic location [10].

Common questions in this guide

How is an LHON variant passed from a mother to her children?
Children receive their mitochondria from their mother, so a woman with an LHON variant can pass it to her children. If nearly all of her mitochondrial DNA carries the variant, transmission to each child is generally expected. If normal and variant mitochondrial DNA are mixed, the amount inherited can differ and a child may have no detectable variant.
If my child inherits an LHON variant, are symptoms certain?
No. Carrying an LHON variant does not guarantee that a child will develop symptoms; some carriers remain healthy throughout life. Population estimates suggest that about half of male carriers and one in ten female carriers eventually develop vision loss, but those figures cannot predict an individual child’s risk or timing.
Does a child’s sex change the chance of LHON vision loss?
Yes. Male carriers are much more likely than female carriers to develop LHON symptoms, although a female carrier can also lose vision. The exact variant, amount of variant, age, broader genetic background, and family history also affect risk.
What visual changes should prompt an LHON evaluation in a child?
Early LHON can cause new, painless blurring or loss of central vision, a blind spot in the center of vision, or difficulty reading and distinguishing colors, especially red and green. In children, changes may begin more slowly or be harder to notice. Any new, unexplained visual change should be evaluated promptly by an ophthalmologist or neuro-ophthalmologist.
What are the benefits and limits of testing a child without symptoms?
Testing can confirm whether an LHON variant is detectable, but it cannot tell you whether or when a child will develop symptoms. Testing a child without symptoms also raises privacy and emotional questions, so families should discuss its benefits and limits with a genetic counselor or clinician familiar with mitochondrial disease.
How can families lower environmental risks for LHON symptoms?
Families should avoid smoking and secondhand smoke, and many specialists advise limiting heavy alcohol use. Do not stop or change a prescribed medicine or eye drop without medical advice; ask clinicians to review potential mitochondrial effects. These steps may reduce risk but cannot guarantee that symptoms will not develop.

Get notified when new evidence is published on Leber hereditary optic neuropathy.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (22)
  1. 1

    Generation of a human iPSC line, FINCBi001-A, carrying a homoplasmic m.G3460A mutation in MT-ND1 associated with Leber's Hereditary optic Neuropathy (LHON).

    Peron C, Mauceri R, Cabassi T, et al.

    Stem cell research 2020; (48()):101939 doi:10.1016/j.scr.2020.101939.

    PMID: 32771908
  2. 2

    Leber Hereditary Optic Neuropathy: Exemplar of an mtDNA Disease.

    Wallace DC, Lott MT

    Handbook of experimental pharmacology 2017; (240()):339-376 doi:10.1007/164_2017_2.

    PMID: 28233183
  3. 3

    Leber's Hereditary Optic Neuropathy-Specific Heteroplasmic Mutation m.14495A>G Found in a Chinese Family.

    Li S, Duan S, Qin Y, et al.

    Translational vision science & technology 2019; (8(4)):3 doi:10.1167/tvst.8.4.3.

    PMID: 31316863
  4. 4

    Mitochondrial genome variation in male LHON patients with the m.11778G > A mutation.

    Piotrowska-Nowak A, Krawczyński MR, Kosior-Jarecka E, et al.

    Metabolic brain disease 2020; (35(8)):1317-1327 doi:10.1007/s11011-020-00605-3.

    PMID: 32740724
  5. 5

    Establishing risk of vision loss in Leber hereditary optic neuropathy.

    Lopez Sanchez MIG, Kearns LS, Staffieri SE, et al.

    American journal of human genetics 2021; (108(11)):2159-2170 doi:10.1016/j.ajhg.2021.09.015.

    PMID: 34670133
  6. 6

    ["Triple-hit" pathogenic mechanism of Leber hereditary optic neuropathy].

    Wang K, Li S, Zhang Y, Guan M

    Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences 2026; (55(7)):683-690 doi:10.3724/zdxbyxb-2025-0868.

    PMID: 42260285
  7. 7

    Incomplete penetrance in mitochondrial optic neuropathies.

    Caporali L, Maresca A, Capristo M, et al.

    Mitochondrion 2017; (36()):130-137 doi:10.1016/j.mito.2017.07.004.

    PMID: 28716668
  8. 8

    Genetic architecture and inheritance patterns of Leber hereditary optic neuropathy among 419 Chinese pedigrees carrying the ND4 11778G>A mutation.

    Ji Y, Meng F, Gao Y, et al.

    Journal of genetics and genomics = Yi chuan xue bao 2026; doi:10.1016/j.jgg.2026.08.007.

    PMID: 42632451
  9. 9

    Cigarette toxicity triggers Leber's hereditary optic neuropathy by affecting mtDNA copy number, oxidative phosphorylation and ROS detoxification pathways.

    Giordano L, Deceglie S, d'Adamo P, et al.

    Cell death & disease 2015; (6()):e2021 doi:10.1038/cddis.2015.364.

    PMID: 26673666
  10. 10

    Leber hereditary optic neuropathy: bridging the translational gap.

    Jurkute N, Yu-Wai-Man P

    Current opinion in ophthalmology 2017; (28(5)):403-409 doi:10.1097/ICU.0000000000000410.

    PMID: 28650878
  11. 11

    Leber hereditary optic neuropathy: current perspectives.

    Meyerson C, Van Stavern G, McClelland C

    Clinical ophthalmology (Auckland, N.Z.) 2015; (9()):1165-76 doi:10.2147/OPTH.S62021.

    PMID: 26170609
  12. 12

    Leber's hereditary optic neuropathy: Update on current diagnosis and treatment.

    Esmaeil A, Ali A, Behbehani R

    Frontiers in ophthalmology 2022; (2()):1077395 doi:10.3389/fopht.2022.1077395.

    PMID: 38983564
  13. 13

    The Eye Drop Preservative Benzalkonium Chloride Potently Induces Mitochondrial Dysfunction and Preferentially Affects LHON Mutant Cells.

    Datta S, Baudouin C, Brignole-Baudouin F, et al.

    Investigative ophthalmology & visual science 2017; (58(4)):2406-2412 doi:10.1167/iovs.16-20903.

    PMID: 28444329
  14. 14

    Mitochondrial disorders and drugs: what every physician should know.

    Orsucci D, Ienco EC, Siciliano G, Mancuso M

    Drugs in context 2019; (8()):212588 doi:10.7573/dic.212588.

    PMID: 31391854
  15. 15

    Toxic medications in Leber's hereditary optic neuropathy.

    Kogachi K, Ter-Zakarian A, Asanad S, et al.

    Mitochondrion 2019; (46()):270-277 doi:10.1016/j.mito.2018.07.007.

    PMID: 30081212
  16. 16

    [Leber's Hereditary Optic Neuropathy].

    Priglinger C, Klopstock T, Rudolph G, Priglinger SG

    Klinische Monatsblatter fur Augenheilkunde 2019; (236(11)):1271-1282 doi:10.1055/a-0972-1552.

    PMID: 31639883
  17. 17

    Leber's Hereditary Optic Neuropathy - Case Discussion.

    Culea C, Tăbăcaru B, Stanca S, Stanca HT

    Romanian journal of ophthalmology 2019; (63(1)):91-101.

    PMID: 31198903
  18. 18

    Childhood-onset Leber hereditary optic neuropathy.

    Majander A, Bowman R, Poulton J, et al.

    The British journal of ophthalmology 2017; (101(11)):1505-1509 doi:10.1136/bjophthalmol-2016-310072.

    PMID: 28314831
  19. 19

    An uncommon cause of vision loss: Leber hereditary optic neuropathy.

    Glover JM, Casmaer ML, April MD

    JAAPA : official journal of the American Academy of Physician Assistants 2018; (31(11)):32-34 doi:10.1097/01.JAA.0000546478.56818.50.

    PMID: 30358677
  20. 20

    Leber Hereditary Optic Neuropathy: Case Report and Literature Review.

    Filatov A, Khanni JL, Espinosa PS

    Cureus 2020; (12(4)):e7745 doi:10.7759/cureus.7745.

    PMID: 32454526
  21. 21

    Leber Hereditary Optic Neuropathy: Support, Genetic Prediction and Accurate Genetic Counselling Enhance Family Planning Choices.

    Kearns LS, Staffieri SE, Mackey DA

    Clinical & experimental ophthalmology 2025; (53(3)):292-301 doi:10.1111/ceo.14493.

    PMID: 39895156
  22. 22

    The Impact of Leber Hereditary Optic Neuropathy on the Quality of Life of Patients and Their Relatives: A Qualitative Study.

    Chen BS, Holzinger E, Taiel M, Yu-Wai-Man P

    Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society 2022; (42(3)):316-322 doi:10.1097/WNO.0000000000001564.

    PMID: 35483081

This page is for informational purposes only and does not constitute medical advice about LHON inheritance or a child’s individual risk. Discuss genetic testing, medication questions, and new vision changes with an ophthalmologist, neuro-ophthalmologist, or genetic counselor.